13F Holdings
中文EN

APRE Aprea Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1781983 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.5%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-62.8%
ROA-53.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.1%
Debt / equity0.00x
Current ratio9.67x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$7.04M$9.36M$7.63M$16.40M$23.90M
SG&A expense$6.48M$6.46M$8.43M$20.97M$13.55M
Operating income-$13.23M-$14.32M-$15.47M-$113.39M-$37.45M
Income tax$0$0$0$0$0
Net income-$12.60M-$12.96M-$14.29M-$112.66M-$37.13M
EBITDA-$13.21M-$14.30M-$15.46M-$113.39M-$37.43M
EPS (basic)-1.93-2.35-3.95-67.99-34.88
EPS (diluted)-1.93-2.35-3.95-67.99-34.88
Weighted avg. shares (diluted)6.54M5.51M3.62M1.66M1.06M
Balance sheet
Cash & equivalents$14.60M$22.89M$21.65M$28.79M$53.08M
Current assets$15.56M$23.58M$22.52M$30.15M$56.58M
PP&E, net$59,807$81,522$88,362$2,321$23,870
Total assets$15.93M$23.98M$22.65M$30.16M$56.82M
Current liabilities$2.76M$3.36M$4.39M$3.20M$7.32M
Total liabilities$3.49M$4.67M$5.70M$3.20M$7.32M
Shareholders' equity$12.44M$19.31M$16.95M$25.64M$49.51M
Shares outstanding8.19M5.48M3.74M2.66M1.09M
Cash flow statement
Operating cash flow-$12.89M-$13.56M-$12.18M-$25.01M-$37.69M
Capital expenditure—$15,478$93,093——
Free cash flow—-$13.57M-$12.27M——
Investing cash flow—-$15,478-$93,093——
Financing cash flow$4.64M$14.82M$5.14M$682,973$1.75M
Depreciation & amortization$21,715$22,318$7,052$4,403$12,829

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.